Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
81.43B
Market cap81.43B
Price-Earnings ratio
19.54
Price-Earnings ratio19.54
Dividend yield
0.47%
Dividend yield0.47%
Average volume
648.24K
Average volume648.24K
High today
$805.68
High today$805.68
Low today
$787.33
Low today$787.33
Open price
$805.30
Open price$805.30
Volume
653.66K
Volume653.66K
52 Week high
$859.34
52 Week high$859.34
52 Week low
$566.11
52 Week low$566.11

Stock Snapshot

The current Regeneron(REGN) stock price is $792.00, with a market capitalization of 81.43B. The stock trades at a price-to-earnings (P/E) ratio of 19.54 and offers a dividend yield of 0.47%.

During the trading session on 2026-10-18, Regeneron(REGN) shares reached a daily high of $805.68 and a low of $787.33. At a current price of $792.00, the stock is +0.6% higher than the low and still -1.7% under the high.

Trading volume for Regeneron(REGN) stock has reached 653.66K, versus its average volume of 648.24K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $566.11.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $566.11.

REGN News

Simply Wall St 15h
Regeneron Pharmaceuticals Could Be 7% Undervalued After Libtayo And Pasatru Updates - Simply Wall Street

...

Regeneron Pharmaceuticals Could Be 7% Undervalued After Libtayo And Pasatru Updates - Simply Wall Street
Simply Wall St 2d
Regeneron Pharmaceuticals Gets EU Backing For Easier Dosing And 84 Week Trial Data

Regeneron Pharmaceuticals (NasdaqGS:REGN) received a positive opinion from the EMA’s CHMP for a new Libtayo dosing schedule across all approved uses. The CHMP-...

Regeneron Pharmaceuticals Gets EU Backing For Easier Dosing And 84 Week Trial Data
TipRanks 2d
Regeneron gets CHMP opinion recommending Libtayo alternative dosing schedule

Regeneron (REGN) announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recomme...

Analyst ratings

65%

of 31 ratings
Buy
64.5%
Hold
29%
Sell
6.5%

More REGN News

Simply Wall St 4d
Regeneron Stock Looks Below Fair Value On Earnings

has delivered solid long term gains for shareholders over the past five years, and a fresh run of clinical and partnership news has pushed investors to reassess...

Regeneron Stock Looks Below Fair Value On Earnings
TipRanks 4d
Regeneron assumed with Buy from Neutral at UBS

UBS upgraded Regeneron (REGN) to Buy from Neutral with a price target of $978, up from $660, after assuming coverage of the name. The shares at current levels a...

Zacks 5d
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's ear...

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
TipRanks 6d
Regeneron announces results from Phase 3 OPTIMA trial of Pasatru

Regeneron (REGN) Pharmaceuticals announced 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru in adults with fibrodysplasia ossificans progressiva...

Simply Wall St 7d
Should Alliance Expansion Require Action From Regeneron Investors?

Regeneron Pharmaceuticals expanded its long running alliance with Sanofi, securing a US$1b upfront payment and sharing rights to four new long acting immunology...

Should Alliance Expansion Require Action From Regeneron Investors?

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.